Dashboard
Manage Tickers

ARGX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

argenx-to-present-vyvgart-and-empasiprubart-data-at-aanem-annual-meeting-and-mgfa-scientific-session-in-san-francisco
Argenx To Present VYVGART And Empasiprubar...
10/15/2025 05:11:31

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis ...

how-do-investors-really-feel-about-argenx-se
How Do Investors Really Feel About argenx SE?
10/13/2025 18:00:52

assessing-argenx-insights-from-12-financial-analysts
Assessing argenx: Insights From 12 Financi...
10/13/2025 14:01:00

tesla-to-300-here-are-10-top-analyst-forecasts-for-monday
Tesla To $300? Here Are 10 Top Analyst For...
10/13/2025 13:43:21

wedbush-maintains-outperform-on-argenx-raises-price-target-to-880
Wedbush Maintains Outperform on argenx, Ra...
10/13/2025 13:04:40

Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $800 to...

morgan-stanley-maintains-overweight-on-argenx-raises-price-target-to-1040
Morgan Stanley Maintains Overweight on arg...
10/01/2025 16:13:30

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $7...

heres-how-much-100-invested-in-argenx-5-years-ago-would-be-worth-today
Here's How Much $100 Invested In argenx 5 ...
09/29/2025 14:31:48

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average an...

price-over-earnings-overview-argenx
Price Over Earnings Overview: argenx
09/26/2025 21:00:29

In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the...

12-analysts-have-this-to-say-about-argenx
12 Analysts Have This To Say About argenx
09/18/2025 21:00:43

guggenheim-reiterates-buy-on-argenx-maintains-1070-price-target
Guggenheim Reiterates Buy on argenx, Maint...
09/18/2025 13:30:50

Guggenheim analyst Yatin Suneja reiterates argenx (NASDAQ:ARGX) with a Buy and maintains $1070 price target.

fujifilm-biotechnologies-expands-strategic-partnership-with-argenx-to-include-us-manufacturing-operations
FUJIFILM Biotechnologies Expands Strategic...
09/18/2025 13:15:05

Expansion of partnership broadens argenx' manufacturing capabilities in the U.S., supporting its strategy of local-for-loca...

truist-securities-maintains-buy-on-argenx-raises-price-target-to-918
Truist Securities Maintains Buy on argenx,...
09/15/2025 13:08:32

Truist Securities analyst Joon Lee maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $700 to $918.

1000-invested-in-argenx-5-years-ago-would-be-worth-this-much-today
$1000 Invested In argenx 5 Years Ago Would...
09/10/2025 22:00:27

is-argenx-gaining-or-losing-market-support
Is argenx Gaining or Losing Market Support?
09/08/2025 19:00:35

b-of-a-securities-maintains-buy-on-argenx-raises-price-target-to-887
B of A Securities Maintains Buy on argenx,...
09/02/2025 15:38:45

B of A Securities analyst Tazeen Ahmad maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $880 to $887.

heres-how-much-100-invested-in-argenx-5-years-ago-would-be-worth-today
Here's How Much $100 Invested In argenx 5 ...
08/27/2025 23:45:19

argenx-immune-disorder-drugs-reach-could-get-much-bigger-with-major-trial-win
Argenx Immune Disorder Drug's Reach Could ...
08/26/2025 17:35:39

Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership i...

regeneron-advances-in-rare-disease-race-with-positive-autoimmune-muscle-disorder-trial-data
Regeneron Advances In Rare Disease Race Wi...
08/26/2025 16:33:47

Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in earl...

piper-sandler-maintains-overweight-on-argenx-raises-price-target-to-820
Piper Sandler Maintains Overweight on arge...
08/26/2025 13:32:28

Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $750...

assessing-argenx-insights-from-11-financial-analysts
Assessing argenx: Insights From 11 Financi...
08/25/2025 19:01:29

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION